ArticleGastroenterology2007
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint.
Article in Gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 77 citations in OpenAlex.
- Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.Digestive diseases and sciences · 2009Trial
- In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis.Alimentary pharmacology & therapeutics · 2009Trial
- Article
- Mucosal kinase activity and inflammatory profiles in inflammatory bowel disease, and in relation to tofacitinib response.Journal of Crohn's & colitis · 2025Article
- Recyclable mesalamine-functionalized magnetic nanoparticles (mesalamine/GPTMS@SiORSC advances · 2023Article
- Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease.Gut and liver · 2022Review
- Portulaca oleracea L. Extract Ameliorates Intestinal Inflammation by Regulating Endoplasmic Reticulum Stress and Autophagy.Molecular nutrition & food research · 2022Article
- Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells.Journal of clinical biochemistry and nutrition · 2022Article
- Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.PloS one · 2022Article
- 5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.British journal of cancer · 2021Article
- Gut Organoid as a New Platform to Study Alginate and Chitosan Mediated PLGA Nanoparticles for Drug Delivery.Marine drugs · 2021Article
- Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation.Scientific reports · 2019Article
- Identification of PMN-released mutagenic factors in a co-culture model for colitis-associated cancer.Carcinogenesis · 2018Article
- 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.Inflammation · 2017Article
- Article
- Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer.Inflammatory bowel diseases · 2015Article
- Chemoprevention of colorectal cancer.Digestive diseases (Basel, Switzerland) · 2015Review
- Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer.International journal of molecular sciences · 2013Review
- Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.Inflammatory bowel diseases · 2013Article
- Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1.Biochemical pharmacology · 2013Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsIndividuals with inflammatory bowel disease are at risk of developing colorectal cancer (CRC). Epidemiologic, animal, and laboratory studies suggest that 5-amino-salicylic acid (5-ASA) protects from the development of CRC by altering cell cycle progression and by inducing apoptosis. Our previous results indicate that 5-ASA improves replication fidelity in colorectal cells, an effect that is active in reducing mutations. In this study, we hypothesized that 5-ASA restrains cell cycle progression by activating checkpoint pathways in colorectal cell lines, which would prevent tumor development and improve genomic stability.
methodsCRC cells with different genetic backgrounds such as HT29, HCT116, HCT116(p53-/-), HCT116+chr3, and LoVo were treated with 5-ASA for 2-96 hours. Cell cycle progression, phosphorylation, and DNA binding of cell cycle checkpoint proteins were analyzed.
resultsWe found that 5-ASA at concentrations between 10 and 40 mmol/L affects cell cycle progression by inducing cells to accumulate in the S phase. This effect was independent of the hMLH1, hMSH2, and p53 status because it was observed to a similar extent in all cell lines under investigation. Moreover, wash-out experiments demonstrated reversibility within 48 hours. Although p53 did not have a causative role, p53 Ser15 was strongly phosphorylated. Proteins involved in the ATM-and-Rad3-related kinase (ATR)-dependent S-phase checkpoint response (Chk1 and Rad17) were also phosphorylated but not ataxia telengectasia mutated kinase.
conclusionsOur data demonstrate that 5-ASA causes cells to reversibly accumulate in S phase and activate an ATR-dependent checkpoint. The activation of replication checkpoint may slow down DNA replication and improve DNA replication fidelity, which increases the maintenance of genomic stability and counteracts carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.